Molecular Partner…
CHCHFMolecular Partners AG (SW:MOLN) — Biotechnology: Biological Products (No Diagnostic Substances). Numărul de burse pe care se tranzacționează acțiunile companiei: 3. Pe această pagină — preț și grafic, dividende, principalii deținători și istoricul numărului de acțiuni.
Despre Companie
- Site Web
- molecularpartners.com
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sediu Central
- Schlieren-Zurich, Switzerland
- Director General
- Patrick Amstutz
- Angajați
- 134
- Listată din
- 03.03.2015 (SW:MOLN)
- Acțiuni în Circulație
- 38.31 mil.
- Free Float
- 20.71 mil.
- Capitalizare de Piață
- 127.56 mil. CHF
- Insideri
- 8.47%
- Investitori Instituționali
- 43.8%
- Industrie (SIC)
- Biological Products, (No Diagnostic Substances)
- Formă Juridică
- MVII
- ISIN
- US60853G1067
- LEI
- 875500AXMLDAZ4D21744
- P/E
- pierdere
- FCF
- −52.0 mil. CHF
- Datorie
- ?
- Câștiguri și FCF — pentru cele 12 luni până la 31.12.2025 (cel mai recent raport al companiei).
Descriere
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Cei Mai Mari Acționari
| Deținător | Participație | Acțiuni | Data Raportului |
|---|---|---|---|
| Old Mission Capital, LLC | 0.03% | 11 347 | 2025-06-30 |
| DFA INVESTMENT DIMENSION… | 0.01% | 3 923 | 2026-07-31 |
| DFA INVESTMENT DIMENSION… | 0.01% | 3 503 | 2026-07-31 |
| American Century ETF Tru… | 0% | 12 | 2026-08-31 |
Conectează-te cu Google